InfuSystem Holdings, Inc (INFU) stock intrinsic value fair value estimate & owner earnings analysis

InfuSystem owns a large fleet of infusion pumps. It makes its money in two ways. Patient Services ($86.5 million of 2025 revenue) supplies ambulatory pumps to oncology clinics and bills Medicare, Medicaid and private insurers for their use. About 43% of this segment's revenue comes from continuous chemotherapy infusion for colorectal cancer. The segment also includes pain management and a fast-growing wound care line. Wound care revenue rose 149% in 2025, helped by the May 2025 purchase of Apollo Medical Supply's assets. Device Solutions ($56.9 million after internal eliminations) rents and sells pumps, sells supplies, and repairs and services other companies' equipment. Total 2025 revenue was $143.4 million, up from $81.1 million in 2019, and it has risen every year since 2018. No single payer or customer made up more than 10% of revenue. How we measure earnings. We start with operating cash flow and take out swings in working capital and stock-based compensation, which we count as a real cost ($4.4 million in 2025). We then subtract the spending needed to keep the pump fleet in service. Pump purchases are the company's main capital cost and they come in uneven batches: $16.7 million in 2024, when rental volume grew, against $8.1 million in 2025, when growth came mostly from wound care, which needs little equipment. The company also regularly gets cash from selling used or lost pumps ($3.3 million in 2025). Because this is a routine part of running the fleet, we net it against purchases. On this basis, earnings for owners were about 35 cents a share in 2023, 14 cents in 2024 and 73 cents in 2025. The 2025 figure is flattered by the light year of pump buying. Our starting level is 35 cents a share, the median of 2023 to 2025. Those three years reflect the company's current size and business mix. Using three years rather than one evens out the pump-buying cycle. Earlier years came from a business 25 to 45% smaller. For comparison, the median across 2020 to 2025 is about 24 cents, and average fleet spending over the past six years puts current earning power nearer 48 cents. We think 35 cents is a fair middle. A fact we built into every case: the company paid only $0.5 million in cash income taxes in 2025 against a $4.0 million tax expense. That gap came partly from using up past losses, and only $5.8 million of federal losses remained at the end of 2025. We assume cash taxes rise from 2027, taking about 5 to 7 cents a share off earnings. Base case, $5.94 a share. During 2025 the company restructured its biomedical services contract with its largest service customer, GE Healthcare. That cuts about $7.1 million of revenue from 2026, but the company expects its costs to fall by even more. First-half 2026 net income of $4.2 million, against $2.3 million a year earlier, is consistent with that. We assume earnings rise 10% in 2026, well below 2025's jump, which came from low pump spending. They then dip in 2027 as cash taxes rise, grow 6% a year through 2030 as oncology and wound care volumes grow and the company keeps buying back shares ($9.9 million of buybacks in 2025), and grow 3% a year through 2035. We then hold earnings flat for twenty more years and assume nothing after that. What supports those later years is the company's structural position: its payer contracts, its Medicare supplier status, and its service centers. We give no value beyond that horizon. Bull case, $10.57 a share. Here the GE savings and wound care growth lift 2026 earnings by 25%. Growth then runs 9% a year through 2030, close to the 8% annual revenue growth from 2020 to 2025 plus some operating leverage, and 5% a year through 2035. Because the clinic and payer network keeps working, earnings then hold flat indefinitely. Bear case, $1.43 a share. Earnings fall back to the lower 2020 to 2025 median of 24 cents and take the tax step-up. They then shrink 3% a year and fade to nothing by the mid-2040s. The risks behind this case are all disclosed in the filing: dependence on continuous-infusion treatment for colorectal cancer, Medicare and Medicaid reimbursement levels and competitive bidding, reliance on Smiths Medical for at least 60% of ambulatory pump purchases, and customer pressure in biomedical services like the GE restructuring. Debt is modest, about $20 million drawn on a $75 million revolving credit line that runs to July 2030, so borrowing does not threaten survival even in this case. What could make this estimate wrong: a change in how colorectal cancer is treated, cuts to reimbursement rates, or pump-buying needs that stay near 2024 levels. Any of these would pull earnings toward the bear case. On the other side, if the savings from the GE restructuring and the shift toward less equipment-heavy wound care keep fleet spending low, the business looks more like the bull case. We could not see first-half 2026 pump purchases in the data available, so we have not confirmed whether 2025's low spending continued.